-$2.77
-$0.65
bear -$2.77
base -$1.67
bull -$0.65
margin of safety $0.00
market price* $2.49
Business condition attached to the margin of safety
A signed multi-year volume supply agreement, with committed prices and quantities, with a smartphone or other device maker, followed by at least two consecutive quarters in which operating cash flow covers capital spending and stock-based pay.
Enovix designs and makes lithium-ion batteries built around a 100% silicon anode and a stacked-cell design, sold as the AI-1 platform for smartphones, smart eyewear and other devices. Almost all current sales, however, come from Routejade, the South Korean electrode-coating and battery-pack maker it bought in October 2023, which sells mainly to defense and industrial customers; batteries for naval munitions were the top product in late 2025. Revenue was $31.8 million in 2025 (up 38%) and $16.6 million in the first half of 2026, with gross margins of 19% and 17%, against operating losses of $177 million in 2025 and $87 million in the first half of 2026. High-volume production is being set up at Fab2 in Penang, Malaysia, after the company wrote off $38.2 million of equipment when it ended volume manufacturing at its original Fremont, California plant in 2024. What owners have actually earned. We measure the cash an owner could take out: operating cash flow, excluding working-capital swings, less stock-based pay (about $49 million in 2025, a real cost paid in new shares) and less the capital spending needed to maintain the business. On that basis the business has lost money every year: about -$52 million in 2020, -$112 million in 2021, -$123 million in 2022, -$237 million in 2023, -$161 million in 2024 and -$139 million in 2025 (-$0.67 per share). Because revenue was rising, we treated most recent capital spending as growth rather than upkeep, which makes these losses smaller, not larger. Adding back interest paid gives the cash the business consumes before its lenders: about -$156 million in 2024 and -$134 million in 2025. We anchor on the median of 2024-2025, about -$145 million a year, the period that describes today's company after the Routejade purchase and the Fremont restructuring; 2023 is left out because it was dominated by building Fab2. The first half of 2026 ran at roughly -$119 million a year, so losses are narrowing, slowly. What is not in any case. Enovix is in formal qualification with two leading smartphone makers (begun in the third quarter of 2025), has sampled nine more smart-eyewear customers, and has one eyewear supply agreement under which it delivered just over 1,000 battery packs. None of this is a volume contract with committed prices and quantities, so no revenue from it is credited in any case. If a qualification turns into a signed multi-year volume order, the valuation should be redone. Debt. At July 5, 2026 the company held about $550 million of cash and investments. It owes $172.5 million of 3.00% convertible notes due 2028 (conversion price $15.61), $360 million of 4.75% convertible notes due 2030 (conversion price $11.21) and about $10 million of Korean bank loans. Because both note coupons are below our 6% rate, we reduce the debt by about $23 million in the base and bull cases to reflect the cheap financing; a small minority interest in the Korean subsidiary is also deducted. That leaves about $29 million of net cash today, but the cash is being consumed at more than $100 million a year and the 2028 notes fall due well before any case shows the losses ending. Bear case: the business keeps consuming about $145 million a year, its 2024-2025 median, for five years, funded as the company has done repeatedly by raising new capital (a $224 million warrant dividend in July 2025, convertible notes in 2023 and 2025), with no credit for cheap debt because refinancing a loss-making borrower would be costly. At the end nothing of value is recovered; the Fremont write-off shows how little specialized battery equipment fetches. The business is worth about -$611 million, cash exceeds debt by about $6 million, and the shares are worth about -$605 million, or -$2.77 per share. Base case: the loss narrows to about $125 million a year, a 7% improvement from 2025 (below the 14% improvement actually achieved in 2025 and consistent with the first half of 2026), and continues for four years while the existing cash lasts; about $50 million is then recovered from plant, inventory and the Korean operation. The business is worth about -$394 million, net cash adds $29 million, and the shares are worth about -$364 million, or -$1.67 per share. Bull case: the loss keeps shrinking by about $20 million a year, the pace achieved from 2024 to 2025, to $115 million, $95 million and $75 million, after which management cuts back to the Korean operating business, as it cut Fremont in 2024, and about $100 million is recovered from plant and the Korean business. The business is worth about -$172 million, net cash adds $29 million, and the shares are worth about -$143 million, or -$0.65 per share. What the shares appear to be worth. In every case the company appears to owe more than it is worth: cash on hand roughly equals the convertible debt, so every dollar the business consumes from here effectively comes from lenders or from new shareholders. The shortfall is about $143 million in the bull case, $364 million in the base case and $605 million in the bear case. A negative figure means the business, on its own record, supports no positive price; the shares carry value only on customer wins that have not happened. No margin-of-safety price is set until a signed volume contract exists and the business stops consuming cash. What would make this wrong: a signed high-volume smartphone or eyewear order at a price that earns a real margin, Fab2 reaching yields and costs that turn today's thin gross margin into meaningful profit, or an acquirer paying for the technology itself. None of these is in hand today.